Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • drop the Hiseqs - get an X10 instead

    In a new episode of Illumina's arbitrary gaming of the sequencing market fight for scientific progress, it opens the X10s and X5s for the resequencing of all genomes:


    Theoretically, this leaves RNA-seq for the Hiseqs.

  • #2
    Originally posted by luc View Post
    In a new episode of Illumina's arbitrary gaming of the sequencing market fight for scientific progress, it opens the X10s and X5s for the resequencing of all genomes:


    Theoretically, this leaves RNA-seq for the Hiseqs.
    Not quite. Illumina is still (arbitrarily) limiting the HiSeq X to "large" genomes. They're trying to encourage (accommodate) large projects sequencing crop species, livestock, model mammalian species, etc. Smaller genomes need not apply.
    AllSeq - The Sequencing Marketplace
    [email protected]
    www.AllSeq.com

    Comment


    • #3
      The press release says:
      " ... will allow for market expansion and population-scale sequencing of non-human species in a variety of markets, including plants and livestock in agricultural research and model organisms in pharmaceutical research. Previously, it has been cost prohibitive to sequence non-human genomes at high coverage. ..."
      This can be anything as far as I can see. Illumina is not going to check on what is being sequenced anyhow.

      Comment


      • #4
        I can't say what Illumina will and won't check, but based on what info we've been able to gather (customer conversations, analyst questions), Illumina definitely intends this to be for large genomes only. That said, I'm not sure how useful such a large platform would be for small genomes - it would take a LOT of samples to fill out a run. But maybe there are ultra-large small genome projects just waiting for this opportunity.
        AllSeq - The Sequencing Marketplace
        [email protected]
        www.AllSeq.com

        Comment


        • #5
          @AllSeq: Analysis of HiSeq X data happens on the attached computer (or in BaseSpace) so this "large" genome restriction could be enforced "inline"?

          It sounds to me like they are opening HiSeq X up for large plant/animal biotech companies that previously could not use HiSeq X. They probably have tens of thousands of samples that could be multiplexed.

          Comment


          • #6
            @GenoMax: We don't use the instruments ourselves, so I'm not really sure about the workflow and exactly how Illumina monitors what's going on. We've heard of a couple of examples of providers 'bending the rules', but it always seems to be with the permission of Illumina. We've never heard of a full-blown 'breach of contract'. Not sure if that elicits a tap on the shoulder from the local FAS or perhaps a friendly call from Jay Flatley? ;-)

            And, yes, I think they're definitely looking to serve the PAG market. It's pretty clear from their quarterly reports (and from what we see on the Sequencing Marketplace) that there's quite a bit of excess X capacity out there. Illumina would love to fill that up (and entice new markets to purchase X's).
            AllSeq - The Sequencing Marketplace
            [email protected]
            www.AllSeq.com

            Comment

            Latest Articles

            Collapse

            • seqadmin
              Understanding Genetic Influence on Infectious Disease
              by seqadmin




              During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.

              Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...
              09-09-2024, 10:59 AM
            • seqadmin
              Addressing Off-Target Effects in CRISPR Technologies
              by seqadmin






              The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...
              08-27-2024, 04:44 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by seqadmin, Today, 06:25 AM
            0 responses
            13 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, Yesterday, 01:02 PM
            0 responses
            12 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 09-18-2024, 06:39 AM
            0 responses
            14 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 09-11-2024, 02:44 PM
            0 responses
            14 views
            0 likes
            Last Post seqadmin  
            Working...
            X